TriSalus Life Sciences (NASDAQ:TLSIW) Trading Up 7.2% – Here’s What Happened

TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) was up 7.2% during mid-day trading on Friday . The company traded as high as $0.9899 and last traded at $1.0610. Approximately 1,565 shares traded hands during trading, a decline of 63% from the average daily volume of 4,212 shares. The stock had previously closed at $0.9899.

TriSalus Life Sciences Trading Up 7.2%

The business’s fifty day moving average price is $1.15 and its 200-day moving average price is $1.27.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Fort Baker Capital Management LP acquired a new position in shares of TriSalus Life Sciences during the fourth quarter valued at about $44,000. Aristeia Capital L.L.C. acquired a new position in shares of TriSalus Life Sciences during the fourth quarter valued at about $43,000. Citadel Advisors LLC grew its holdings in shares of TriSalus Life Sciences by 439.0% during the third quarter. Citadel Advisors LLC now owns 126,876 shares of the company’s stock valued at $199,000 after buying an additional 103,336 shares during the last quarter. Finally, Cerity Partners LLC acquired a new position in shares of TriSalus Life Sciences during the fourth quarter valued at about $1,374,000.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage medical device company focused on developing minimally invasive technologies to enhance the precision and efficacy of cancer radiation therapy. The company’s lead product, the TriMark™ Tissue Marker System, is designed to provide high-visibility soft-tissue fiducial markers that assist oncologists in accurately targeting tumors during radiotherapy. By deploying bio-absorbable markers directly into tumor beds, TriSalus aims to improve treatment planning, patient comfort and long-term follow-up imaging.

Founded in 2015 and headquartered in Plymouth, Minnesota, TriSalus Life Sciences pursues a platform approach to oncology treatment, with research and development efforts centered on novel delivery devices and advanced imaging solutions.